Treating the Full Spectrum of Narcolepsy: Improving Nighttime Symptoms to Enhance Daytime Quality of Life: Live Q&A with Dr. Bogan, Session II
neuroscienceCME WebcastPremiere Date: Wednesday, October 19, 2016
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, October 19, 2017
Note: Credit Is No Longer Available
|Thomas Roth, PhD
Chief, Division Head
Sleep Disorders and Research Center
Henry Ford Hospital
|Richard K. Bogan, MD, FCCP, FAASM
Chief Medical Officer, SleepMed Inc.
Director, SleepMed of South Carolina
Associate Clinical Professor
University of South Carolina School of Medicine
Associate Clinical Professor
Medical University of South Carolina
|Todd J. Swick, MD
Clinical Assistant Professor of Neurology
University of Texas Medical School Health Sciences Center at Houston
Medical Director, Apnix Sleep Diagnositics
Memorial and Katy Sleep Centers
Medical Director, The Sleep Center at North Cypress Medical Center
Patients with narcolepsy often face a long journey on their path to diagnosis and effective treatment. Combating the negative impact of narcolepsy on the lives of those affected requires that both the general public and the medical community increase their awareness of the symptoms of narcolepsy, in particular, the most common presenting symptoms: cataplexy and excessive daytime sleepiness.
Improved recognition of both symptoms and objective measures of narcolepsy can shorten the burdensome lag from symptom onset to effective treatment and improve the lives of people with this life-altering central disorder of hypersomnolence. Although a cure for narcolepsy is not available, effective treatments are currently available and more are on the horizon.
In this neuroscienceCME Expert Connection Module, faculty will discuss screening strategies for patients with possible narcolepsy, applying AASM quality measures for diagnosis of narcolepsy, and prescribing evidence-based treatment.
At the end of this CE activity, participants should be able to:
- Prescribe evidence-based treatment for all patients with narcolepsy within one month of diagnosing the narcolepsy.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Define evidence-based treatment for all patients with narcolepsy that can be used within one month of diagnosing the narcolepsy.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Primary care physicians, physician assistants, nurse practitioners, nurses, and pharmacists who manage patients with narcolepsy.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1 contact hours
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1 contact hour of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1 contact hours (0.10 CEUs) Universal Activity Number: 0376-0000-16-027-L01-P (live program) and 0376-0000-16-027-H01-P (recorded program)
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Roth has disclosed that he serves on the speakers bureau for Merck. He is a consultant for Cereve; Flamel Technologies SA; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Proctor & Gamble; Pfizer Inc.; SEQ
Dr. Bogan has disclosed that he receives research support from Actelion Pharmaceuticals US, Inc.; Apenex Medical, Inc.; ApniCure, Inc.; Balance; Beckman Coulter, Inc.; Bioavivus Inc.; Boehringer Ingelheim; Eisai Inc.; Fisher Paykel; GlaxoSmithKline; Jazz Pharmaceuticals, Inc.; Johnson & Johnson; Merck & Co., Inc.; Novo Nordisk; Philips; Pfizer Inc.; ResMed;; Sensory Medical, Inc.; Vanda Pharmaceuticals; XenoPort, Inc. He serves on the speakers bureau for Cephalon, Inc.; Jazz Pharmaceuticals, Inc.; Teva Pharmaceuticals USA; XenoPort, Inc. He is a consultant for Aerial BioPharma LLC; Jazz Pharmaceuticals, Inc.; Teva Pharmaceuticals USA. He is the chief medical officer, member of the board of directors, and employee of SleepMed, Inc. His other financial income sources or equity include the board of directors for First Community Corporation, SC and National Sleep Foundation.
Dr. Swick has disclosed that he receives research support from Jazz Pharmaceuticals, Inc. He serves on the speakers bureau for Jazz Pharmaceuticals, Inc. He is a consultant for Jazz Pharmaceuticals, Inc.
Tony Graham, MD (peer reviewer) has no disclosures to report.
Kimberley Murray, RN, MS (peer reviewer) has no disclosures to report.
Catherine Murray (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP (planning committee) has no disclosures to report.
Jan Perez, CHCP (planning committee) has no disclosures to report
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and Jazz Pharmaceuticals Inc. do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).